Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kanglaite + anlotinib
- Development stage
- Preclinical
- Lead developer
- Zhejiang Kanglaite Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Kanglaite + anlotinib is a combination therapy that pairs two anti-cancer agents with different mechanisms of action. Kanglaite (KLT) is a traditional Chinese medicine preparation derived from Coix seed oil, while anlotinib is a multi-targeted tyrosine kinase inhibitor. This combination is being investigated for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The combination aims to leverage Kanglaite's ability to improve efficacy and reduce toxicity of conventional treatments alongside anlotinib's antiangiogenic and anti-tumor properties.
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR (FGFR family)
Beyond the preview
Go deeper on Kanglaite + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kanglaite + anlotinib.